The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics Session at SITC25
Society for Immunotherapy of Cancer (SITC) shared a post on LinkedIn:
“SITC25 Science Preview: Join Kristen Hege, MD, Board Member, Mersana, Adaptimmune, Kelonia, KSQ and EvolveImmune, Zhen Su, MD MBA, Marengo Therapeutics, Daina Graybosch, PhD, Leerink Partners, Ashley Koegel, MD, Bristol Myers Squibb, Brad Loncar, BBA, BiotechTV and Allen S. Yang, MD, PhD, Summit Therapeutics in the session, ‘The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics’.
This session will cover recent data from these next gen approaches and include a panel discussion on the state of the cancer “and beyond” immunotherapy field including both opportunities and obstacles for developing the next wave of breakthrough therapeutics.
View session details and register for SITC’s 40th Anniversary Annual Meeting.
Early registration ends Aug. 13.”
More posts featuring Society for Immunotherapy of Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023